Recently, Chinese researchers published the results of their research using a gene-editing technology on abnormal human zygotes. The research team believes this research has prospective clinical application, viz., for gene therapy for β-thalassemia, a white blood cell disorder, and plan to persist with further studies, despite technical problems in this experiment. The research has elicited international criticism from both scientific and bioethics domains, because it innovates beyond the current global consensus against human germ line modification. This paper comments on some ethical issues presented by the research report and concludes that, under present circumstances, the Chinese research team did not meet a standard of scientific responsibility.
In a section of the paper entitled, "Compliance with Ethics Guidelines," the authors declare that the study (1) "conformed to ethical standards of the Helsinki Declaration, (2) "was approved by the Medical Ethical Committee" of the affiliate hospital, and (3) the 3PN zygotes were donated with "signed informed consent forms." Informed consent and human subjects (IRB) review are standard requirements for this kind of research, of course. The Helsinki Declaration, revised most recently in October 2013, addresses human subjects research and, pertinent to this experiment, "research on identifiable human material" 2 . Thus, the authors signal their responsibility relative to "applicable international norms and standards," including "generally accepted scientific principles." In this sense, then, it would seem the research conducted here is not prohibited either by extant applicable international norms and standards or by any applicable generally accepted scientific principles.
Discussion: Notwithstanding, the foregoing summary of experimental results raises any number of ethical questions. The most important concerns the fact that the research team decided to use human embryos, albeit IVF-discarded abnormal polyspermic zygotes. Citing earlier experimental work, the authors recognize there has been "great progress in understanding the utilization of CRISPR/Cas9 in a variety of model organisms," in which case it is clear that current research designs can investigate the molecular mechanism of CRISPR/Cas9 and progress adequately when undertaken in model organisms other than human embryos Another group, publishing in Nature on 12 March 2015, argued that, given "unpredictable effects on future generations" that follow from use of "genome editing in human embryos using current technologies," not to mention that this type of research "could be exploited for non-therapeutic modifications," therefore this research is "ethically unacceptable" 6 . So long as there are other non-human organisms that can serve as effective models for this kind of research, it is generally thought that there is no scientific or moral warrant for use of such geneediting technology on human embryos. Thus, the appeal is to (a) generally accepted scientific principles, (b) the current standard of research in animal models such as mice, rats, monkeys, cattle, sheep, and pigs, as well as to (c) morally relevant assessments of benefit (safety, efficiency) and risk (unintended and unpredictable adverse harm from on-target editing and off-target mutations). The Chinese research clearly ventured beyond currently accepted research models, these models providing the responsible-use "paradigm" according to which researchers demonstrate their compliance with internationally sanctioned norms. As the Nature authors write, . But, the
Council "strongly opposes the use of germline gene modification in humans," based on "scientific, ethical, and social concerns"-the "scientific," including inefficiency of techniques used in mammals, unintended adverse harm observed in mouse models (e.g., mice lacking eyes, lacking "the semicircular canals of their inner ears"),
and, yet more problematic, "developmental disruptions in the manipulated embryo itself;" the "ethical," including the fact that foregoing pregnancy, prenatal genetic diagnosis, abortion, and adoption are morally defensible options; "social," in the sense of identifying and implementing relevant social measures that are enabling, short of genetic enhancement.
At issue in the foregoing discussions is a concern for scientific integrity in such research and thus what a report Conclusion: Clearly, the question about public regulatory mechanisms is not a matter to be governed only by national guidelines, even if the research is not directed towards human reproduction as such. It is research that must be responsive to global policy concerns about human germ line modification, precisely because this is a transnationally human interest that is not contained by sovereign political right or nationally derived public policy.
The Chinese researchers have not exercised their scientific freedom according to this concept of responsibility, in which case one can only conclude that this particular research should not have been done at this particular time.
